TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06679140: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID

Sponsor: Pfizer · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 2330 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,600,088

Rescue Site Savings

+$5,677,728

Unlock Full NCT06679140 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06679140 Rescue Dossier →